vs

Side-by-side financial comparison of Castellum, Inc. (CTM) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $12.6M, roughly 1.6× Castellum, Inc.). Castellum, Inc. runs the higher net margin — -10.5% vs -66.3%, a 55.8% gap on every dollar of revenue. On growth, Castellum, Inc. posted the faster year-over-year revenue change (21.9% vs -8.7%). Over the past eight quarters, Castellum, Inc.'s revenue compounded faster (5.3% CAGR vs -0.5%).

Castellum, Inc. is a U.S.-based cybersecurity and information technology services provider. It caters to government defense agencies, public sector entities, and commercial enterprise clients, offering threat detection, data protection, cloud security, and managed IT solutions to help organizations mitigate cyber risks and safeguard critical digital infrastructure.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

CTM vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.6× larger
LUNG
$20.6M
$12.6M
CTM
Growing faster (revenue YoY)
CTM
CTM
+30.6% gap
CTM
21.9%
-8.7%
LUNG
Higher net margin
CTM
CTM
55.8% more per $
CTM
-10.5%
-66.3%
LUNG
Faster 2-yr revenue CAGR
CTM
CTM
Annualised
CTM
5.3%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CTM
CTM
LUNG
LUNG
Revenue
$12.6M
$20.6M
Net Profit
$-1.3M
$-13.7M
Gross Margin
33.9%
77.9%
Operating Margin
-11.1%
-40.9%
Net Margin
-10.5%
-66.3%
Revenue YoY
21.9%
-8.7%
Net Profit YoY
51.8%
5.5%
EPS (diluted)
$-0.02
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTM
CTM
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$12.6M
$22.6M
Q3 25
$14.6M
$21.5M
Q2 25
$14.0M
$23.9M
Q1 25
$11.7M
$22.5M
Q4 24
$10.3M
$23.8M
Q3 24
$11.6M
$20.4M
Q2 24
$11.5M
$20.8M
Net Profit
CTM
CTM
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-1.3M
$-10.4M
Q3 25
$415.4K
$-14.0M
Q2 25
$-322.1K
$-15.2M
Q1 25
$-1.2M
$-14.4M
Q4 24
$-2.7M
$-13.2M
Q3 24
$-1.3M
$-14.1M
Q2 24
$-1.8M
$-15.3M
Gross Margin
CTM
CTM
LUNG
LUNG
Q1 26
77.9%
Q4 25
33.9%
77.6%
Q3 25
37.6%
74.7%
Q2 25
36.1%
72.1%
Q1 25
39.0%
72.5%
Q4 24
40.0%
74.0%
Q3 24
42.7%
73.7%
Q2 24
40.6%
73.7%
Operating Margin
CTM
CTM
LUNG
LUNG
Q1 26
-40.9%
Q4 25
-11.1%
-43.8%
Q3 25
3.0%
-66.9%
Q2 25
-2.7%
-62.0%
Q1 25
-12.7%
-64.6%
Q4 24
-15.7%
-56.5%
Q3 24
-11.9%
-69.3%
Q2 24
-13.6%
-75.2%
Net Margin
CTM
CTM
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-10.5%
-46.1%
Q3 25
2.8%
-64.9%
Q2 25
-2.3%
-63.6%
Q1 25
-10.0%
-64.1%
Q4 24
-26.6%
-55.4%
Q3 24
-11.0%
-69.4%
Q2 24
-16.0%
-73.7%
EPS (diluted)
CTM
CTM
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.02
$-0.25
Q3 25
$0.00
$-0.34
Q2 25
$0.00
$-0.38
Q1 25
$-0.01
$-0.36
Q4 24
$-0.05
$-0.33
Q3 24
$-0.02
$-0.36
Q2 24
$-0.03
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTM
CTM
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$35.8M
$45.8M
Total Assets
$41.9M
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTM
CTM
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$76.5M
Q2 25
$75.5M
Q1 25
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
CTM
CTM
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$8.0M
$37.2M
Q3 24
$8.3M
$37.2M
Q2 24
$8.7M
$37.2M
Stockholders' Equity
CTM
CTM
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$35.8M
$54.1M
Q3 25
$36.7M
$60.0M
Q2 25
$31.8M
$69.1M
Q1 25
$26.1M
$77.7M
Q4 24
$20.2M
$85.8M
Q3 24
$12.0M
$93.9M
Q2 24
$12.1M
$101.2M
Total Assets
CTM
CTM
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$41.9M
$129.3M
Q3 25
$46.3M
$138.3M
Q2 25
$43.4M
$147.2M
Q1 25
$41.1M
$150.7M
Q4 24
$37.8M
$162.8M
Q3 24
$28.8M
$167.4M
Q2 24
$29.5M
$172.6M
Debt / Equity
CTM
CTM
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.40×
0.43×
Q3 24
0.69×
0.40×
Q2 24
0.72×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTM
CTM
LUNG
LUNG
Operating Cash FlowLast quarter
$-661.7K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTM
CTM
LUNG
LUNG
Q1 26
Q4 25
$-661.7K
$-7.1M
Q3 25
$1.0M
$-8.2M
Q2 25
$214.2K
$-3.9M
Q1 25
$-2.5M
$-13.2M
Q4 24
$-394.4K
$-6.7M
Q3 24
$742.2K
$-7.2M
Q2 24
$748.6K
$-5.8M
Free Cash Flow
CTM
CTM
LUNG
LUNG
Q1 26
Q4 25
$-7.1M
Q3 25
$957.0K
$-8.3M
Q2 25
$-4.0M
Q1 25
$-13.5M
Q4 24
$-6.8M
Q3 24
$738.9K
$-7.7M
Q2 24
$-6.2M
FCF Margin
CTM
CTM
LUNG
LUNG
Q1 26
Q4 25
-31.4%
Q3 25
6.5%
-38.4%
Q2 25
-16.6%
Q1 25
-60.0%
Q4 24
-28.8%
Q3 24
6.4%
-37.6%
Q2 24
-30.0%
Capex Intensity
CTM
CTM
LUNG
LUNG
Q1 26
Q4 25
0.1%
Q3 25
0.3%
0.4%
Q2 25
0.2%
Q1 25
1.3%
Q4 24
0.0%
0.5%
Q3 24
0.0%
2.0%
Q2 24
0.0%
2.3%
Cash Conversion
CTM
CTM
LUNG
LUNG
Q1 26
Q4 25
Q3 25
2.41×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons